Loading…

HDR Brachytherapy in the Management of High-Risk Prostate Cancer

High-dose-rate (HDR) brachytherapy is used with increasing frequency for the treatment of prostate cancer. It is a technique which allows delivery of large individual fractions to the prostate without exposing adjacent normal tissues to unacceptable toxicity. This approach is particularly favourable...

Full description

Saved in:
Bibliographic Details
Published in:Advances in Urology 2012-01, Vol.2012 (2012), p.798-803
Main Authors: Masson, Susan, Persad, Raj, Bahl, Amit
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-a638t-54312c29e8e56f5f6b6bac62ceb25356cd211282b5e63e84b294e3a1730c44ca3
cites cdi_FETCH-LOGICAL-a638t-54312c29e8e56f5f6b6bac62ceb25356cd211282b5e63e84b294e3a1730c44ca3
container_end_page 803
container_issue 2012
container_start_page 798
container_title Advances in Urology
container_volume 2012
creator Masson, Susan
Persad, Raj
Bahl, Amit
description High-dose-rate (HDR) brachytherapy is used with increasing frequency for the treatment of prostate cancer. It is a technique which allows delivery of large individual fractions to the prostate without exposing adjacent normal tissues to unacceptable toxicity. This approach is particularly favourable in prostate cancer where tumours are highly sensitive to dose escalation and to increases in radiotherapy fraction size, due to the unique radiobiological behaviour of prostate cancers in contrast with other malignancies. In this paper we discuss the rationale and the increasing body of clinical evidence for the use of this technique in patients with high-risk prostate cancer, where it is combined with external beam radiotherapy. We highlight practical aspects of delivering treatment and discuss toxicity and limitations, with particular reference to current practice in the United Kingdom.
doi_str_mv 10.1155/2012/980841
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_98c415397e8340cb96f303f4c37e553c</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><airiti_id>P20151223003_201212_201703140007_201703140007_798_803</airiti_id><doaj_id>oai_doaj_org_article_98c415397e8340cb96f303f4c37e553c</doaj_id><sourcerecordid>963493136</sourcerecordid><originalsourceid>FETCH-LOGICAL-a638t-54312c29e8e56f5f6b6bac62ceb25356cd211282b5e63e84b294e3a1730c44ca3</originalsourceid><addsrcrecordid>eNqFkcuP0zAQhyMEYpeFE2dQbkigsLbHzwsCyqMrFbFawdmauJPWpU2Kk4L63-NtloqeOM3Y8-nz41cUTzl7zblSl4Jxcekss5LfK865tqbSYMz9Y6_dWfGo71eMaW6NeVicCSE1N46fF2-nH27K9wnDcj8sKeF2X8a2zG35BVtc0IbaoeyachoXy-om9j_K69T1Aw5UTrANlB4XDxpc9_Tkrl4U3z99_DaZVrOvn68m72YVarBDpSRwEYQjS0o3qtG1rjFoEagWCpQOc8G5sKJWpIGsrIWTBMgNsCBlQLgorkbvvMOV36a4wbT3HUZ_2OjSwmMaYliTdzZIrsAZsiBZqJ1ugEEjAxhSCkJ2vRld2129oXnIb0y4PpGeTtq49IvulwfhNFcsC17cCVL3c0f94DexD7ReY0vdrvdOg3TAQWfy1UiG_G19ouZ4Cmf-Nj5_G58f48v0838vdmT_5pWBlyOwjO0cf8f_2J6NMGWEGjzCioM4zGfjHGOKQ_SrbpfanKG_zhbFhQDG4GDMzlwMAy4ZY-Z0YZz1lgH8AQh6vho</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>963493136</pqid></control><display><type>article</type><title>HDR Brachytherapy in the Management of High-Risk Prostate Cancer</title><source>Wiley Open Access</source><source>PubMed Central</source><creator>Masson, Susan ; Persad, Raj ; Bahl, Amit</creator><contributor>Spahn, Martin</contributor><creatorcontrib>Masson, Susan ; Persad, Raj ; Bahl, Amit ; Spahn, Martin</creatorcontrib><description>High-dose-rate (HDR) brachytherapy is used with increasing frequency for the treatment of prostate cancer. It is a technique which allows delivery of large individual fractions to the prostate without exposing adjacent normal tissues to unacceptable toxicity. This approach is particularly favourable in prostate cancer where tumours are highly sensitive to dose escalation and to increases in radiotherapy fraction size, due to the unique radiobiological behaviour of prostate cancers in contrast with other malignancies. In this paper we discuss the rationale and the increasing body of clinical evidence for the use of this technique in patients with high-risk prostate cancer, where it is combined with external beam radiotherapy. We highlight practical aspects of delivering treatment and discuss toxicity and limitations, with particular reference to current practice in the United Kingdom.</description><identifier>ISSN: 1687-6369</identifier><identifier>EISSN: 1687-6377</identifier><identifier>DOI: 10.1155/2012/980841</identifier><identifier>PMID: 22461791</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Limiteds</publisher><subject>Review</subject><ispartof>Advances in Urology, 2012-01, Vol.2012 (2012), p.798-803</ispartof><rights>Copyright © 2012 Susan Masson et al.</rights><rights>Copyright © 2012 Susan Masson et al. 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a638t-54312c29e8e56f5f6b6bac62ceb25356cd211282b5e63e84b294e3a1730c44ca3</citedby><cites>FETCH-LOGICAL-a638t-54312c29e8e56f5f6b6bac62ceb25356cd211282b5e63e84b294e3a1730c44ca3</cites><orcidid>0000-0001-7747-0412</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3296150/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3296150/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22461791$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Spahn, Martin</contributor><creatorcontrib>Masson, Susan</creatorcontrib><creatorcontrib>Persad, Raj</creatorcontrib><creatorcontrib>Bahl, Amit</creatorcontrib><title>HDR Brachytherapy in the Management of High-Risk Prostate Cancer</title><title>Advances in Urology</title><addtitle>Adv Urol</addtitle><description>High-dose-rate (HDR) brachytherapy is used with increasing frequency for the treatment of prostate cancer. It is a technique which allows delivery of large individual fractions to the prostate without exposing adjacent normal tissues to unacceptable toxicity. This approach is particularly favourable in prostate cancer where tumours are highly sensitive to dose escalation and to increases in radiotherapy fraction size, due to the unique radiobiological behaviour of prostate cancers in contrast with other malignancies. In this paper we discuss the rationale and the increasing body of clinical evidence for the use of this technique in patients with high-risk prostate cancer, where it is combined with external beam radiotherapy. We highlight practical aspects of delivering treatment and discuss toxicity and limitations, with particular reference to current practice in the United Kingdom.</description><subject>Review</subject><issn>1687-6369</issn><issn>1687-6377</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNqFkcuP0zAQhyMEYpeFE2dQbkigsLbHzwsCyqMrFbFawdmauJPWpU2Kk4L63-NtloqeOM3Y8-nz41cUTzl7zblSl4Jxcekss5LfK865tqbSYMz9Y6_dWfGo71eMaW6NeVicCSE1N46fF2-nH27K9wnDcj8sKeF2X8a2zG35BVtc0IbaoeyachoXy-om9j_K69T1Aw5UTrANlB4XDxpc9_Tkrl4U3z99_DaZVrOvn68m72YVarBDpSRwEYQjS0o3qtG1rjFoEagWCpQOc8G5sKJWpIGsrIWTBMgNsCBlQLgorkbvvMOV36a4wbT3HUZ_2OjSwmMaYliTdzZIrsAZsiBZqJ1ugEEjAxhSCkJ2vRld2129oXnIb0y4PpGeTtq49IvulwfhNFcsC17cCVL3c0f94DexD7ReY0vdrvdOg3TAQWfy1UiG_G19ouZ4Cmf-Nj5_G58f48v0838vdmT_5pWBlyOwjO0cf8f_2J6NMGWEGjzCioM4zGfjHGOKQ_SrbpfanKG_zhbFhQDG4GDMzlwMAy4ZY-Z0YZz1lgH8AQh6vho</recordid><startdate>20120101</startdate><enddate>20120101</enddate><creator>Masson, Susan</creator><creator>Persad, Raj</creator><creator>Bahl, Amit</creator><general>Hindawi Limiteds</general><general>Hindawi Puplishing Corporation</general><general>Hindawi Publishing Corporation</general><general>Hindawi Limited</general><scope>188</scope><scope>ADJCN</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-7747-0412</orcidid></search><sort><creationdate>20120101</creationdate><title>HDR Brachytherapy in the Management of High-Risk Prostate Cancer</title><author>Masson, Susan ; Persad, Raj ; Bahl, Amit</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a638t-54312c29e8e56f5f6b6bac62ceb25356cd211282b5e63e84b294e3a1730c44ca3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Masson, Susan</creatorcontrib><creatorcontrib>Persad, Raj</creatorcontrib><creatorcontrib>Bahl, Amit</creatorcontrib><collection>Airiti Library</collection><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access Journals</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Advances in Urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Masson, Susan</au><au>Persad, Raj</au><au>Bahl, Amit</au><au>Spahn, Martin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>HDR Brachytherapy in the Management of High-Risk Prostate Cancer</atitle><jtitle>Advances in Urology</jtitle><addtitle>Adv Urol</addtitle><date>2012-01-01</date><risdate>2012</risdate><volume>2012</volume><issue>2012</issue><spage>798</spage><epage>803</epage><pages>798-803</pages><issn>1687-6369</issn><eissn>1687-6377</eissn><abstract>High-dose-rate (HDR) brachytherapy is used with increasing frequency for the treatment of prostate cancer. It is a technique which allows delivery of large individual fractions to the prostate without exposing adjacent normal tissues to unacceptable toxicity. This approach is particularly favourable in prostate cancer where tumours are highly sensitive to dose escalation and to increases in radiotherapy fraction size, due to the unique radiobiological behaviour of prostate cancers in contrast with other malignancies. In this paper we discuss the rationale and the increasing body of clinical evidence for the use of this technique in patients with high-risk prostate cancer, where it is combined with external beam radiotherapy. We highlight practical aspects of delivering treatment and discuss toxicity and limitations, with particular reference to current practice in the United Kingdom.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Limiteds</pub><pmid>22461791</pmid><doi>10.1155/2012/980841</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0001-7747-0412</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1687-6369
ispartof Advances in Urology, 2012-01, Vol.2012 (2012), p.798-803
issn 1687-6369
1687-6377
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_98c415397e8340cb96f303f4c37e553c
source Wiley Open Access; PubMed Central
subjects Review
title HDR Brachytherapy in the Management of High-Risk Prostate Cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T14%3A07%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=HDR%20Brachytherapy%20in%20the%20Management%20of%20High-Risk%20Prostate%20Cancer&rft.jtitle=Advances%20in%20Urology&rft.au=Masson,%20Susan&rft.date=2012-01-01&rft.volume=2012&rft.issue=2012&rft.spage=798&rft.epage=803&rft.pages=798-803&rft.issn=1687-6369&rft.eissn=1687-6377&rft_id=info:doi/10.1155/2012/980841&rft_dat=%3Cproquest_doaj_%3E963493136%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a638t-54312c29e8e56f5f6b6bac62ceb25356cd211282b5e63e84b294e3a1730c44ca3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=963493136&rft_id=info:pmid/22461791&rft_airiti_id=P20151223003_201212_201703140007_201703140007_798_803&rfr_iscdi=true